8-amino-adenosine is a potential therapeutic agent for multiple myeloma

Molecular Cancer Therapeutics

Volumn 3, Issue 11, 2004, Pages 1411-1419

  Krett, Nancy L ^a   Davies, Katherine M ^a   Ayres, Mary ^b   Ma, Chunguang ^a   Nabhan, Chadi ^a   Gandhi, Varsha ^b   Rosen, Steven T ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 AMINOADENOSINE; 8 CHLOROADENOSINE; ADENOSINE DERIVATIVE; ADENOSINE KINASE; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLISOLEUCYLGLUTAMYLTHREONYLASPARTYL FLUOROMETHYL KETONE; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE; GLUCOCORTICOID; LIPOCORTIN 5; STAUROSPORINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL COUNT; CELL LEVEL; CELL MEMBRANE POTENTIAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA CONTENT; DNA SYNTHESIS; DOSE RESPONSE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL LINE; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN BINDING; RNA SYNTHESIS;

ADENOSINE; APOPTOSIS; CASPASES; CELL LINE, TUMOR; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; HUMANS; MOLECULAR STRUCTURE; MULTIPLE MYELOMA; PHOSPHORYLATION; POLYPHOSPHATES; RNA;

EID: 9444251209     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Attal M, Haroussequ JL, Stoppa AM, et al. A prospective, randomize trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996;335:91-7.
3. Hjertner O, Borset M, Waage A. Comparison of the effects of 2-chlorodeoxyadenosine and melphalan in myeloma cell lines. Leuk Res 1996;20:155-60.
4. Oken M. New agents for the treatment of multiple myeloma and non-Hodgkin lymphoma. Cancer 1992;70:946-8.
5. Gandhi V, Plunkett W. Combination strategies for purine nucleoside analogs. New York: Marcel Dekker, Inc.; 2001. p. 195-208.
6. Plunkett W, Gandhi V. Purine and pyrimidine nucleoside analogs. Cancer Chemother Biol Response Modif 2001;19:21-45.
7. Nagourney RA, Evans SS, Messenger JC, Su YZ, Weisenthal LM. 2 Chlorodeoxyadenosine activity and cross resistance patterns in primary cultures of human hematologic neoplasms. Br J Cancer 1993;67:10-4.
8. Lichman SM, Mittelman A, Budman DR, et al. Phase II trials of fludarabine phosphate in multiple myeloma using a loading dose and continuous infusion schedule. Leuk Lymphoma 1991;6:61-3.
9. Kraut EH, Crowley JJ, Grever MR. Phase II study of fludarabine phosphate in multiple myeloma. Invest New Drugs 1990;8:199-200.
10. Gandhi V, Ayres M, Halgren RG, et al. 8-chloro-cAMP and 8-chloro-adenosine act by the same mechanism in multiple myeloma cells. Cancer Res 2001;61:5474-9.
11. Koontz JW, Wicks WD. Cytotoxic effects of two novel 8-substituted cyclic nucleotide derivatives in cultured rat hepatoma cells. Mol Pharmacol 1980;18:65-71.
12. Boe R, Gjertsen BT, Doskeland SO, Vintermyr OK. 8-Chloro-cAMP induces apoptotic cell death in a human mammary carcinoma cell (MCF-7) line. Br J Cancer 1995;72:1151-9.
13. 1-S transition in mammary carcinoma cells (MCF-7). Endocrinology 1995;136:2513-20.
14. Saito M, Nasu A, Kataoka S, Ohshita K, Yamaji N. Cytotoxic effect of 8-amino adenosine 3′,5′-cyclic monophosphate on FM3A mouse mammary tumor cells. J Pharmacobiodyn 1989;12:357-62.
15. Goldman-Leikin RE, Salwen HR, Herst CV, et al. Characterization of a novel myeloma cell line. J Lab Clin Invest 1989;113:335-45.
16. Moalli PA, Pillay S, Weiner D, Leikin R, Rosen ST. A mechanism of resistance to glucocorticoids in multiple myeloma: transient expression of a truncated glucocorticoid receptor mRNA. Blood 1992;79:213-22.
17. Bellamy WT, Dalton WS, Gleason MC, Grogan TM, Trent JM. Development and characterization of a melphalan-resistant human multiple myeloma cell line. Cancer Res 1991;51:995-1002.
18. Cory JG, Carter GL. Leukemia L1210 cell lines resistant to ribonucleotide reductase inhibitors. Cancer Res 1988;48:839-43.
19. Krett NL, Zell JL, Halgren RG, et al. Cyclic adenosine-3′, 5′-monophosphate-mediated cytotoxicity in steroid sensitive and resistant myeloma. Clin Cancer Res 1997;3:1781-7.
20. Xie C, Plunkett W. Metabolism and actions of 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-adenine in human lymphoblastoid cells. Cancer Res 1995;55:2847-52.
21. Gandhi V, Danhauser L, Plunkett W. Separation of 1-β-D-arabinofuranosylcytosine 5′-triphosphate and 9-β-D-arabinofuranosyl-2-fluoroadenine 5′-triphosphate in human leukemia cells by high-performance liquid chromatography. J Chromotogr 1987;413:293-9.
22. Gandhi V, Chen W, Ayres M, et al. Plasma and cellular pharmacology of 8-chloro-adenosine in mice and rats. Cancer Chemother Pharmacol 2002;50:85-94.
23. Ferri KF, Kroemer G. Mitochondria - the suicide organelles. Bioessays 2001;23:111-5.
24. Li H, Zhu H, Xu C-J, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998;94:491-501.
25. Halgren RG, Traynor AE, Pillay S, et al. 8Cl-cAMP cytotoxicity in both steroid sensitive and insensitive multiple myeloma cell lines is mediated by 8Cl-adenosine. Blood 1998;92:2893-8.
26. Pawelczyk T, Sakowicz M, Podgorska M, Szczepanska-Konkel M. Insulin induces expression of adenosine kinase gene in rat lymphocytes by signaling through the mitogen-activated protein kinase pathway. Exp Cell Res 2003;286:152-63.
27. Huang P, Plunkett W. Action of 9-β-D arabinofuranosyl-2-fluroradenine on RNA metabolism. Mol Pharmacol 1991;39:449-55.
28. Costantini P, Jacotot E, Decaudin D, Kroemer G. Mitochondrion as a novel target of anticancer chemotherapy. J Natl Cancer Inst 2000; 92:1042-53.
29. Pirnia F, Schneider E, Betticher DC, Borner MM. Mitomycin C induces apoptosis and caspase-8 and -9 processing through a caspase-3 and Fas-independent pathway. Cell Death Differ 2002;9:905-14.
30. You KR, Shin MN, Park RK, Lee SO, Kim DG. Activation of caspase-8 during N-(4-hydroxyphenyl)retinamide-induced apoptosis in Fas-defective hepatoma cells. Hepatology 2001;34:1119-27.
31. Ferrari D, Stepczynska A, Los M, Wesselborg S, Schulze-Osthoff K. Differential regulation and ATP requirement for caspase-8 and caspase-3 activation during CD95- and anticancer drug-induced apoptosis. J Exp Med 1998;188:979-84.
32. Wieder T, Essmann F, Prokop A, et al. Activation of caspase-8 in drug-induced apoptosis of B-lymphoid cells is independent of CD95/Fas receptor-ligand interaction and occurs downstream of caspase-3. Blood 2001;97:1378-87.
33. Wilson PK, Szabados E, Mulligan SP, Christopherson RI. Comparative effects of cladribine, fludarabine and pentostatin on nucleotide metabolism in T- and B-cell lines. Int J Biochem Cell Biol 1998;30:833-42.
34. Parker WB, Shaddix SC, Chang CH, et al. Effects of 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-triphosphate. Cancer Res 1991; 51:2386-94.